Objective：To explore the expression and significance of arachidonate 12-lipoxygenase（ALOX12）in cancer tissues of colon cancer patients. Methods：Tumor and peritumoral tissues of 257 colon cancer patients were retrospectively collected，and the expression of ALOX12 was detected by immunohistochemistry（IHC）to compare the differences in expression within the tumor and peritumoral tissues，and the relationship between ALOX12 expression and clinicopathological features of colon cancer was analyzed. The 5-year overall survival（OS）of the patients was analyzed using Kaplan-Meier curves，and the factors affecting the 5-year OS of the patients were investigated by univariate and multivariate Cox regression analyses. Results：ALOX12 was more positively expressed in tumors compared to peritumoral tissues（63.8% vs. 33.1%），and the difference was statistically significant（P < 0.001）. The expression of ALOX12 was not significantly correlated with the patient’s age，gender，and tumor site（P > 0.05），but was strongly correlated with TNM staging and lymph node metastasis（P < 0.05）. Five-year OS of patients with high expression of ALOX12 was markedly lower than those patients with low expression of ALOX12（P < 0.001）. Single variable and multivariate Cox analyses indicated that age，TNM staging，lymph node metastasis，and ALOX12 expression were independent factors influencing the 5-year OS rate（P < 0.05）. Conclusion：High expression of ALOX12 is associated with TNM staging and lymph node metastasis of colon cancer，which can serve as a biomarker to predict the patient’s condition and prognosis.